Oruka Therapeutics, Inc.
ORKAHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeOruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I). With a market capitalization of $3.33B, it sits in mid-cap territory. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Market Cap
$3.33B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-22.43
EPS (TTM)
$-1.93
EPS (Fwd)
$-2.46
ROE
-27.3%
ROA
-18.9%
Cash
$388.8M
Total Debt
$1.8M
Free CF
-$56.1M
52W Change
372.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $388.8M in cash comfortably exceeding the $1.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$56.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -27.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ORKA.